Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:2840065rdf:typepubmed:Citationlld:pubmed
pubmed-article:2840065lifeskim:mentionsumls-concept:C0086418lld:lifeskim
pubmed-article:2840065lifeskim:mentionsumls-concept:C0005821lld:lifeskim
pubmed-article:2840065lifeskim:mentionsumls-concept:C0018296lld:lifeskim
pubmed-article:2840065lifeskim:mentionsumls-concept:C1510827lld:lifeskim
pubmed-article:2840065lifeskim:mentionsumls-concept:C0871161lld:lifeskim
pubmed-article:2840065pubmed:issue1lld:pubmed
pubmed-article:2840065pubmed:dateCreated1988-8-18lld:pubmed
pubmed-article:2840065pubmed:abstractTextEffect of 8-arginine vasopressin (AVP) was examined on human platelet membrane GTPase activity as an index of a G-protein involvement. AVP stimulated a high-affinity GTPase activity in a dose-dependent manner (Kact = 1.1 +/- 0.2 nM). This stimulation was blocked by a V1a antagonist, thus confirming the V1a nature of the platelet AVP receptor. There were important variations among individuals in the AVP-induced stimulation of GTPase activity, that were in relation with the AVP-maximal binding capacity. These data suggest a causal relationship between the binding of AVP to its receptor and transduction elicited by a G-protein, without amplification. In addition, in view of the variable AVP responsiveness observed among individuals, platelet AVP-receptor appears to be subject to regulation.lld:pubmed
pubmed-article:2840065pubmed:languageenglld:pubmed
pubmed-article:2840065pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2840065pubmed:citationSubsetIMlld:pubmed
pubmed-article:2840065pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2840065pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2840065pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2840065pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2840065pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2840065pubmed:statusMEDLINElld:pubmed
pubmed-article:2840065pubmed:monthJullld:pubmed
pubmed-article:2840065pubmed:issn0006-291Xlld:pubmed
pubmed-article:2840065pubmed:authorpubmed-author:ChevillardCClld:pubmed
pubmed-article:2840065pubmed:authorpubmed-author:MathieuM NMNlld:pubmed
pubmed-article:2840065pubmed:authorpubmed-author:CantauBBlld:pubmed
pubmed-article:2840065pubmed:authorpubmed-author:VittetDDlld:pubmed
pubmed-article:2840065pubmed:issnTypePrintlld:pubmed
pubmed-article:2840065pubmed:day15lld:pubmed
pubmed-article:2840065pubmed:volume154lld:pubmed
pubmed-article:2840065pubmed:ownerNLMlld:pubmed
pubmed-article:2840065pubmed:authorsCompleteYlld:pubmed
pubmed-article:2840065pubmed:pagination213-8lld:pubmed
pubmed-article:2840065pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:2840065pubmed:meshHeadingpubmed-meshheading:2840065-...lld:pubmed
pubmed-article:2840065pubmed:meshHeadingpubmed-meshheading:2840065-...lld:pubmed
pubmed-article:2840065pubmed:meshHeadingpubmed-meshheading:2840065-...lld:pubmed
pubmed-article:2840065pubmed:meshHeadingpubmed-meshheading:2840065-...lld:pubmed
pubmed-article:2840065pubmed:meshHeadingpubmed-meshheading:2840065-...lld:pubmed
pubmed-article:2840065pubmed:meshHeadingpubmed-meshheading:2840065-...lld:pubmed
pubmed-article:2840065pubmed:meshHeadingpubmed-meshheading:2840065-...lld:pubmed
pubmed-article:2840065pubmed:meshHeadingpubmed-meshheading:2840065-...lld:pubmed
pubmed-article:2840065pubmed:meshHeadingpubmed-meshheading:2840065-...lld:pubmed
pubmed-article:2840065pubmed:meshHeadingpubmed-meshheading:2840065-...lld:pubmed
pubmed-article:2840065pubmed:year1988lld:pubmed
pubmed-article:2840065pubmed:articleTitleProperties of vasopressin-activated human platelet high affinity GTPase.lld:pubmed
pubmed-article:2840065pubmed:affiliationINSERM U.300, Faculté de Pharmacie, Montpellier, France.lld:pubmed
pubmed-article:2840065pubmed:publicationTypeJournal Articlelld:pubmed